Alzheimer's Development Financing: Risky Therapies Call for Innovative Deals

 
• By Chris Morrison

Eli Lilly has hedged its bets on its two late-stage Alzheimer's disease candidates. In a deal with TPG-Axon and Quintiles' partnering group NovaQuest, Lilly sheds risk (and potentially reward) in this notoriously difficult therapeutic space. A model for private equity / pharma deals going forward?

More from Business Strategy

More from In Vivo